Immunomedics Could Face Second FDA Rejection For Breast Cancer Drug, Goldman Sachs Days In Double Downgrade
Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'
Immunomedics Could Face Second FDA Rejection For Breast Cancer Drug, Goldman Sachs Days In Double Downgrade
Nektar Hit With Double Downgrade From Goldman: 'Significant Challenges In Rebuilding Confidence'
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Here's What Was Intriguing About Incyte's Q3 Report